Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of DPYD pharmacogenetic variation in Mexican patients with gastrointestinal malignancies.

Cancer chemotherapy and pharmacology - 17 Sept 2026

Gonzalez-Covarrubias Vanessa, Morales-Alfaro Andrea, Bonilla-Jimenez Oscar, Rodríguez-Dorantes Mauricio, Frías-Jimenez Emmanuel, Soto-Perez-de-Celis Enrique

Abstract excerpt

PURPOSE: Fluoropyrimidines are among the most widely used chemotherapeutic agents for gastrointestinal malignancies, but interindividual variability in dihydropyrimidine dehydrogenase (DPD) activity, encoded by DPYD, can lead to severe or lethal toxicities. Most pharmacogenetic data on DPYD originates from European populations, limiting the applicability of current guidelines in admixed groups. METHODS: We...

Read the complete abstract on PubMed

Topics

Humans
Dihydrouracil Dehydrogenase (NADP)
Female
Mexico
Gastrointestinal Neoplasms
Male

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Aged

Middle Aged

Gene Frequency

Genotype

Prospective Studies

Adult

Pharmacogenetics

Antimetabolites, Antineoplastic

Polymorphism, Single Nucleotide

Fluorouracil

Pharmacogenomic Variants

Genome-Wide Association Study

Source

Identifiers

PMID: 42752660
DOI: 10.1007/s00280-026-04955-0

Genes

DPYD
FGF12
MTHFR
SDK1
TYMS
ZPBP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of DPYD pharmacogenetic variation in Mexican patients with gastrointestinal malignancies.PMID 42752660Read ↗

Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the LiteratureSemantic proximity Read ↗

Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.Semantic proximity Read ↗

Relevance of the c.557A>G variant for the implementation of DPYD pharmacogenetics in populations with Afro-Latin American ancestry.Semantic proximity Read ↗

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in GreeceSemantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.Semantic proximity Read ↗

Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population.Semantic proximity Read ↗

Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and OpportunitiesSemantic proximity Read ↗

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD VariantsSemantic proximity Read ↗

DPYD genotyping and predicting fluoropyrimidine toxicity: where do we stand?Semantic proximity Read ↗

Opportunistic analysis of clinically actionable DPYD gene variants in a germline testing cohort in India.Semantic proximity Read ↗

All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly GuideSemantic proximity Read ↗

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.